Abstract 278

Background:

Overactive JAK-STAT signaling as a result of gain-of-function mutations (eg, JAK2V617F) and/or high circulating levels of inflammatory cytokines is considered to play a key role in the pathogenesis of myeloproliferative neoplasms. Ruxolitinib, a selective oral inhibitor of JAK1 and JAK2, demonstrated a significant reduction in spleen volume (SV) and improvements in myelofibrosis (MF)-related symptoms in a double-blind placebo-controlled trial (COMFORT-I). The objective of this analysis was to evaluate the efficacy of ruxolitinib across patient (pt) subgroups in COMFORT-I.

Methods:

Pts with MF were randomized to start placebo or ruxolitinib at a dose of 15 mg or 20 mg PO BID depending on baseline platelet count (100–200 ×109/L or >200 ×109/L, respectively). The dose was optimized for efficacy and safety during treatment. SV change was measured by MRI; MF symptoms were assessed using a daily diary (modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0) over 1 wk prior to dosing and throughout the 24 wks of dosing. The percent changes from baseline to wk 24 in SV and MFSAF Total Symptom Score (TSS, a measure of combined scores for abdominal discomfort, pain under ribs on left side, early satiety, itching, night sweats, and bone/muscle pain) were compared for ruxolitinib and placebo pts across the following subgroups: MF disease subtype, age, International Prognosis Scoring System (IPSS) risk group, presence/absence of JAK2V617F mutation, baseline hemoglobin, baseline spleen size (palpable spleen length), and baseline TSS. Survival was estimated by Kaplan-Meier method.

Changes in SV and TSS Across Subgroups:

309 pts were randomized: 155 to ruxolitinib and 154 to placebo. Ruxolitinib demonstrated consistent benefit compared with placebo in both SV and TSS across all subgroups evaluated (Table).

Mean Percent Change From Baseline to Wk 24 ± SD

SubgroupSV
TSS
RuxolitinibPlaceboRuxolitinibPlacebo
Primary MF −29.9 ± 17.5 +8.5 ± 16.7 −38.5 ± 54.3 +41.7 ± 92.0 
Post-Polycythemia Vera MF −37.3 ± 20.9 +5.9 ± 14.5 −54.9 ± 41.5 +27.2 ± 105 
Post-Essential Thrombocythemia MF −27.0 ± 17.4 +11.1 ± 11.2 −49.9 ± 45.1 +73.7 ± 112 
High Risk −30.9 ± 19.5 +7.7 ± 15.8 −41.5 ± 52.2 +48.7 ± 94.8 
Intermediate-2 Risk −32.8 ± 18.4 +9.1 ± 14.5 −53.5 ± 43.2 +28.8 ± 107 
Age ≤65 −31.1 ± 18.8 +12.7 ± 15.6 −48.1 ± 46.6 +28.6 ± 73.0 
Age >65 −32.2 ± 19.3 +6.3 ± 14.9 −45.0 ± 50.6 +47.7 ± 109 
V617F Positive −34.6 ± 19.8 +8.1 ± 16.5 −52.6 ± 44.9 +42.8 ± 98.6 
V617F Negative −23.8 ± 14.2 +8.4 ± 8.5 −28.1 ± 55.5 +37.2 ± 105 
Baseline Palpable Spleen Length ≤10 cm −26.8 ± 19.1 +13.0 ± 11.7 −28.5 ± 56.6 +39.1 ± 116 
Baseline Palpable Spleen Length >10 cm −32.9 ± 18.9 +6.9 ± 15.9 −51.1 ± 45.4 +42.4 ± 95.5 
Baseline Hb ≥10 g/dL −33.4 ± 18.7 +7.6 ± 16.1 −47.0 ± 49.6 +27.2 ± 99.7 
Baseline Hb <10 g/dL −28.3 ± 19.2 +8.9 ± 14.3 −45.6 ± 47.1 +63.8 ± 95.6 
SubgroupSV
TSS
RuxolitinibPlaceboRuxolitinibPlacebo
Primary MF −29.9 ± 17.5 +8.5 ± 16.7 −38.5 ± 54.3 +41.7 ± 92.0 
Post-Polycythemia Vera MF −37.3 ± 20.9 +5.9 ± 14.5 −54.9 ± 41.5 +27.2 ± 105 
Post-Essential Thrombocythemia MF −27.0 ± 17.4 +11.1 ± 11.2 −49.9 ± 45.1 +73.7 ± 112 
High Risk −30.9 ± 19.5 +7.7 ± 15.8 −41.5 ± 52.2 +48.7 ± 94.8 
Intermediate-2 Risk −32.8 ± 18.4 +9.1 ± 14.5 −53.5 ± 43.2 +28.8 ± 107 
Age ≤65 −31.1 ± 18.8 +12.7 ± 15.6 −48.1 ± 46.6 +28.6 ± 73.0 
Age >65 −32.2 ± 19.3 +6.3 ± 14.9 −45.0 ± 50.6 +47.7 ± 109 
V617F Positive −34.6 ± 19.8 +8.1 ± 16.5 −52.6 ± 44.9 +42.8 ± 98.6 
V617F Negative −23.8 ± 14.2 +8.4 ± 8.5 −28.1 ± 55.5 +37.2 ± 105 
Baseline Palpable Spleen Length ≤10 cm −26.8 ± 19.1 +13.0 ± 11.7 −28.5 ± 56.6 +39.1 ± 116 
Baseline Palpable Spleen Length >10 cm −32.9 ± 18.9 +6.9 ± 15.9 −51.1 ± 45.4 +42.4 ± 95.5 
Baseline Hb ≥10 g/dL −33.4 ± 18.7 +7.6 ± 16.1 −47.0 ± 49.6 +27.2 ± 99.7 
Baseline Hb <10 g/dL −28.3 ± 19.2 +8.9 ± 14.3 −45.6 ± 47.1 +63.8 ± 95.6 
View Large

The impact of symptom severity on response was evaluated by baseline TSS quartiles (maximum score for TSS = 60). Ruxolitinib pts with baseline TSS of <8.5, 8.5-<16.5, 16.5-<25.5 and ≥25.5 had mean percent changes in SV of −28.0, −31.4, −31.7 and −34.8, respectively, vs +8.1 for all placebo pts combined. The mean percent change in TSS for these same subgroups was −40.5, −47.2, −48.1 and −48.2 vs +41.8 for all placebo pts combined. These data indicate that pts with modest to marked symptoms all benefit from ruxolitinib therapy in terms of both SV and TSS.

Survival Analysis:

13 ruxolitinib and 24 placebo pts died during the study or during extended follow-up (median follow-up of 52 and 51 wks, respectively), representing a hazard ratio (95% CI) of 0.499 (0.254, 0.98) (p=0.0395). For ruxolitinib- and placebo-treated pts, respectively, the probability of survival (95% CI) >48 wks was 0.98 (0.92, 0.99) and 0.90 (0.81, 0.95) for pts with baseline hemoglobin values ≥10 g/dL and 0.84 (0.72, 0.91) and 0.77 (0.63, 0.86) for pts with baseline hemoglobin <10 g/dL.

Conclusions:

Pts receiving ruxolitinib had higher response rates than placebo based on reductions in SV and improvements in TSS at wk 24 regardless of baseline subgroup: MF disease subtype, age (≤65 or >65 y), IPSS risk group (intermediate-2 or high-risk), presence or absence of JAK2V617F mutation, hemoglobin level (≥10 g/dL or <10 g/dL), palpable spleen length (≤10 cm or >10 cm), and symptom severity (TSS quartile). In addition, the overall survival analysis suggested a benefit with ruxolitinib therapy over placebo.

Disclosures:

Verstovsek:Incyte: Research Funding. Mesa:Incyte: Research Funding; Lilly: Research Funding; SBio: Research Funding; Astra Zeneca: Research Funding; NS Pharma: Research Funding; Celgene: Research Funding. Gotlib:Incyte: Consultancy, Research Funding. Levy:Incyte: Employment, Equity Ownership. Gupta:Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Catalano:Incyte: Honoraria; Novartis: Honoraria. Deininger:BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Ariad: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding; Genzyme: Research Funding. Miller:Incyte: Research Funding; Novartis: Honoraria, Research Funding, Speakers Bureau. Winton:Incyte: Consultancy. Arcasoy:Incyte: Research Funding. Lyons:Alexion: Consultancy, Honoraria; Telik: Research Funding; Incyte: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Novartis: Research Funding. Vaddi:Incyte: Employment. Erickson-Viitanen:Incyte: Employment. Sun:Incyte: Employment. Sandor:Incyte: Employment. Kantarjian:Incyte: Research Funding; Novartis: Consultancy, Research Funding.

Topics:
comfort-i trial, ruxolitinib, spleen, brachial plexus neuritis, hemoglobin, follow-up, myelofibrosis, prostatic hypertrophy risk score, abdominal pain, cytokine

Author notes

*

Asterisk with author names denotes non-ASH members.

This icon denotes a clinically relevant abstract

© 2011 by The American Society of Hematology
2011
Sign in via your Institution